Incyte advances its Opzelura eczema campaign with a ‘reimagine’ theme
Incyte’s newest campaign for Opzelura (ruxolitinib) encourages itchy patients to “Reimagine Relief” as it works to carve out a niche in the crowded eczema treatment category.
That niche? It’s a topical, steroid-free option for patients who don’t like needles in a category rife with typically first-recommended topical corticosteroids. It appeals to people hesitant to take an oral systemic biologic.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
